The drug is indicated for the treatment of salt and water retention caused by heart failure or kidney diseases
Alembic Pharmaceuticals has received approval from the US health regulator for Metolazone tablets, indicated for the treatment of salt and water retention caused by heart failure or kidney disease.
The approved product is therapeutically equivalent to the reference listed drug product Zaroxolyn Tablets 2.5 mg, 5 mg and 10 mg of Lannett Company, Inc.
In a regulatory filing, Alembic Pharmaceuticals stated, “It has received approval from the US Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg.”
Metolazone tablets are indicated for the treatment of salt and water retention such as oedema accompanying congestive heart failure, oedema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.
Metolazone tablets are also indicated for the treatment of hypertension, either alone or in combination with other antihypertensive drugs of another class.
Quoting IQVIA data, Alembic Pharma stated Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg have an estimated market size of $33 million to 12 months ending September 2020.
PTI
